Skip to main content Accessibility help
×
Home

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study

  • Diego Quattrone (a1) (a2) (a3), Laura Ferraro (a4), Giada Tripoli (a5), Caterina La Cascia (a4), Harriet Quigley (a5), Andrea Quattrone (a6), Hannah E. Jongsma (a7), Simona Del Peschio (a8), Giusy Gatto (a8), EU-GEI group (a1), Charlotte Gayer-Anderson (a9), Peter B. Jones (a10) (a11), James B. Kirkbride (a7), Daniele La Barbera (a4), Ilaria Tarricone (a12), Domenico Berardi (a12), Sarah Tosato (a13), Antonio Lasalvia (a13), Andrei Szöke (a14), Celso Arango (a15), Miquel Bernardo (a16), Julio Bobes (a17), Cristina Marta Del Ben (a18), Paulo Rossi Menezes (a18), Pierre-Michel Llorca (a19), Jose Luis Santos (a20), Julio Sanjuán (a21), Andrea Tortelli (a22), Eva Velthorst (a23) (a24), Lieuwe de Haan (a23), Bart P. F. Rutten (a25), Michael T. Lynskey (a26), Tom P. Freeman (a26) (a27), Pak C. Sham (a28) (a29), Alastair G. Cardno (a30), Evangelos Vassos (a1), Jim van Os (a25) (a31), Craig Morgan (a9), Ulrich Reininghaus (a3) (a9) (a25), Cathryn M. Lewis (a1), Robin M. Murray (a2) (a5) and Marta Di Forti (a1) (a2)...

Abstract

Background

Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients.

Method

We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We used item response modelling to estimate two bifactor models, which included general and specific dimensions of psychotic symptoms in patients and psychotic experiences in controls. The associations between these dimensions and cannabis use were evaluated using linear mixed-effects models analyses.

Results

In patients, there was a linear relationship between the positive symptom dimension and the extent of lifetime exposure to cannabis, with daily users of high-potency cannabis having the highest score (B = 0.35; 95% CI 0.14–0.56). Moreover, negative symptoms were more common among patients who never used cannabis compared with those with any pattern of use (B = −0.22; 95% CI −0.37 to −0.07). In controls, psychotic experiences were associated with current use of cannabis but not with the extent of lifetime use. Neither patients nor controls presented differences in depressive dimension related to cannabis use.

Conclusions

Our findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potency types.

Copyright

Corresponding author

Author for correspondence: Diego Quattrone, E-mail: diego.quattrone@kcl.ac.uk

Footnotes

Hide All
*

See at the end of the Article for more details.

Footnotes

References

Hide All
Addington, J., & Addington, D. (2007). Patterns, predictors and impact of substance use in early psychosis: A longitudinal study. Acta Psychiatrica Scandinavica, 115, 304309.
Barrowclough, C., Gregg, L., Lobban, F., Bucci, S., & Emsley, R. (2015). The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophrenia Bulletin, 41, 382390.
Bernhardson, G., & Gunne, L. M. (1972). Forty-six cases of psychosis in cannabis abusers. International Journal of the Addictions, 7, 916.
Bersani, G., Orlandi, V., Kotzalidis, G. D., & Pancheri, P. (2002). Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience, 252, 8692.
Boydell, J., Dean, K., Dutta, R., Giouroukou, E., Fearon, P., & Murray, R. (2007). A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Schizophrenia Research, 93, 203210.
Bromberg, W. (1934). Marihuana intoxication. The American Journal of Psychiatry, 91, 303330.
Chopra, G. S., & Smith, J. W. (1974). Psychotic reactions following cannabis use in east Indians. Archives of General Psychiatry, 30, 2427.
Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., … Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry, 2, 233238.
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., … Murray, R. M. (2009). High-potency cannabis and the risk of psychosis. The British Journal of Psychiatry, 195, 488491.
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., … Murray, R. M. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet Psychiatry, 6, 427436.
Dubertret, C., Bidard, I., Ades, J., & Gorwood, P. (2006). Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research, 86, 284290.
ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in Cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biological Psychiatry, 79, 613619.
European Monitoring Centre for Drugs and Drug Addiction (2013). European drug report: Trends and developments. Luxembourg, Luxembourg: Publications Office of the European Union. Doi:10.2810/88175.
Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Capuccio, V., … Di Forti, M. (2019). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. Schizophrenia Bulletin. Advance online publication. doi:10.1093/schbul/sbz077.
Ferraro, L., Russo, M., O'Connor, J., Wiffen, B. D., Falcone, M. A., Sideli, L., … Di Forti, M. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophrenia Research, 150, 129135.
Foti, D. J., Kotov, R., Guey, L. T., & Bromet, E. J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. The American Journal of Psychiatry, 167, 987993.
Freeman, T. P., Groshkova, T., Cunningham, A., Sedefov, R., Griffiths, P., & Lynskey, M. T. (2019). Increasing potency and price of cannabis in Europe, 2006–16. Addiction, 114, 10151023.
Freeman, T. P., Morgan, C. J., Hindocha, C., Schafer, G., Das, R. K., & Curran, H. V. (2014). Just say ‘know’: How do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction, 109, 16861694.
Freeman, T. P., van der Pol, P., Kuijpers, W., Wisselink, J., Das, R. K., Rigter, S., … Lynskey, M. T. (2018). Changes in cannabis potency and first-time admissions to drug treatment: A 16-year study in the Netherlands. Psychological Medicine, 48, 23462352.
Grech, A., Van Os, J., Jones, P. B., Lewis, S. W., & Murray, R. M. (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry, 20, 349353.
Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A., Glick, I., … Group, H. R. (2004). First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophrenia Research, 66, 125135.
Hancock, G. R., & Mueller, R. O. (2001). Rethinking construct reliability within latent variable systems. In Cudek, R., Du Toit, S. & Sorbom, D. (Eds.), Structural equation modeling: Present and future: A festschrift in honor of karl jöreskog (pp. 195216). Linconlnwood, IL: Scientific Software International, Inc.
Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Mule, A., & Szoke, A., … European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package, G. (2018). Treated incidence of psychotic disorders in the multinational EU-GEI Study. JAMA Psychiatry, 75, 3646.
Large, M. M., Smith, G., Sara, G., Paton, M. B., Kedzior, K. K., & Nielssen, O. B. (2012). Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings. International Journal of Methods in Psychiatric Research, 21, 134148.
Mallett, R. (1997). Sociodemographic schedule. Section of Social Psychiatry. Institute of Psychiatry, 183.
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 12621269.
McGuffin, P., Farmer, A., & Harvey, I. (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry, 48, 764770.
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., … Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. The American Journal of Psychiatry, 175, 225231.
Morrison, P., Zois, V., McKeown, D., Lee, T., Holt, D., Powell, J., … Murray, R. (2009). The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 39, 16071616.
Murray, R. M., Englund, A., Abi-Dargham, A., Lewis, D. A., Di Forti, M., Davies, C., … D'Souza, D. C. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89104.
Muthén, L., & Muthén, B. (2012). Mplus user's guide (7th ed.). Los Angeles, CA: Muthén & Muthén.
Negrete, J. C., Knapp, W. P., Douglas, D. E., & Smith, W. B. (1986). Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychological Medicine, 16, 515520.
Peralta, V., & Cuesta, M. J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scandinavica, 85, 127130.
Potter, D. J., Hammond, K., Tuffnell, S., Walker, C., & Di Forti, M. (2018). Potency of Delta(9)-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Testing and Analysis, 10, 628635.
Quattrone, D., Di Forti, M., Gayer-Anderson, C., Ferraro, L., Jongsma, H. E., Tripoli, G., … Reininghaus, U. (2019). Transdiagnostic dimensions of psychopathology at first episode psychosis: Findings from the multinational EU-GEI study. Psychological Medicine, 49, 13781391.
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R., & Del-Ben, C. M. (2018). Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the community assessment of psychic experiences. Early intervention in psychiatry, 12, 10131023.
Ringen, P. A., Nesvag, R., Helle, S., Lagerberg, T. V., Lange, E. H., Loberg, E. M., … Melle, I. (2016). Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. Psychological Medicine, 46, 31273136.
Rodriguez, A., Reise, S. P., & Haviland, M. G. (2016). Applying bifactor statistical indices in the evaluation of psychological measures. Journal of Personality Assessment, 98, 223237.
Ruiz-Veguilla, M., Callado, L. F., & Ferrin, M. (2012). Neurological soft signs in patients with psychosis and cannabis abuse: A systematic review and meta-analysis of paradox. Current Pharmaceutical Design, 18, 51565164.
Schoeler, T., Petros, N., Di Forti, M., Klamerus, E., Foglia, E., Ajnakina, O., … Bhattacharyya, S. (2016). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. The Lancet Psychiatry, 3, 947953.
Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research, 130, 216221.
Seddon, J. L., Birchwood, M., Copello, A., Everard, L., Jones, P. B., Fowler, D., … Singh, S. P. (2016). Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: A report from the UK national EDEN Study. Schizophrenia Bulletin, 42, 619625.
Spencer, D. J. (1971). Cannabis-induced psychosis. International Journal of the Addictions, 6, 323326.
StataCorp, L. (2015). Stata Statistical Software: Release 14 [computer program]. StataCorp LP.
Stefanis, N. C., Hanssen, M., Smirnis, N. K., Avramopoulos, D. A., Evdokimidis, I. K., Stefanis, C. N., … Van Os, J. (2002). Evidence that three dimensions of psychosis have a distribution in the general population. Psychological Medicine, 32, 347358.
Stirling, J., Lewis, S., Hopkins, R., & White, C. (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophrenia Research, 75, 135137.
Talbott, J. A., & Teague, J. W. (1969). Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. Jama, 210, 299302.
Taylor, M., Sullivan, J., Ring, S. M., Macleod, J., & Hickman, M. (2017). Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people. Addiction, 112, 477485.
Thornicroft, G., Meadows, G., & Politi, P. (1992). Is ‘cannabis psychosis’ a distinct category? European Psychiatry, 7, 277282.
Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K., … Group, P.-V. (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research, 47, 438444.
van Dijk, D., Koeter, M. W., Hijman, R., Kahn, R. S., & van den Brink, W. (2012). Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophrenia Research, 137, 5057.
Wolford, G. L., Rosenberg, S. D., Drake, R. E., Mueser, K. T., Oxman, T. E., Hoffman, D., … Carrieri, K. L. (1999). Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychology of Addictive Behaviors, 13, 313326.
Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. The British Journal of Psychiatry, 193, 357363.

Keywords

Type Description Title
WORD
Supplementary materials

Quattrone et al. supplementary material
Quattrone et al. supplementary material

 Word (584 KB)
584 KB

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study

  • Diego Quattrone (a1) (a2) (a3), Laura Ferraro (a4), Giada Tripoli (a5), Caterina La Cascia (a4), Harriet Quigley (a5), Andrea Quattrone (a6), Hannah E. Jongsma (a7), Simona Del Peschio (a8), Giusy Gatto (a8), EU-GEI group (a1), Charlotte Gayer-Anderson (a9), Peter B. Jones (a10) (a11), James B. Kirkbride (a7), Daniele La Barbera (a4), Ilaria Tarricone (a12), Domenico Berardi (a12), Sarah Tosato (a13), Antonio Lasalvia (a13), Andrei Szöke (a14), Celso Arango (a15), Miquel Bernardo (a16), Julio Bobes (a17), Cristina Marta Del Ben (a18), Paulo Rossi Menezes (a18), Pierre-Michel Llorca (a19), Jose Luis Santos (a20), Julio Sanjuán (a21), Andrea Tortelli (a22), Eva Velthorst (a23) (a24), Lieuwe de Haan (a23), Bart P. F. Rutten (a25), Michael T. Lynskey (a26), Tom P. Freeman (a26) (a27), Pak C. Sham (a28) (a29), Alastair G. Cardno (a30), Evangelos Vassos (a1), Jim van Os (a25) (a31), Craig Morgan (a9), Ulrich Reininghaus (a3) (a9) (a25), Cathryn M. Lewis (a1), Robin M. Murray (a2) (a5) and Marta Di Forti (a1) (a2)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.